Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc.(NASDAQ: RXST) for potential violations of the federal securities laws.

If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit.

Why is RxSight being Investigated?

RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company’s main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens’s shape and power to optimize vision based on the patient’s individual needs and preferences.

During the relevant period, the Company touted its strong LAL and LDD sales. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024.

The Stock Declines as the Truth is Revealed

On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a “softening” of the market that purportedly occurred “in the second half of 2024.” On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025.

Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to “the slower ramp in LAL utilization that was first noted in 2024.” On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025.

Click here for more information: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit.

What Can You Do?

If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250717070133/en/